Gene knockdown is an experimental technique by which the expression of one or more of an organism's genes is reduced. The reduction can occur either through genetic modification or by treatment with a reagent such as a short DNA or RNA oligonucleotide that has a sequence complementary to either gene or an mRNA transcript.
Versus transient knockdown
If a DNA of an organism is genetically modified, the resulting organism is called a "knockdown organism." If the change in gene expression is caused by an oligonucleotide binding to an mRNA or temporarily binding to a gene, this leads to a temporary change in gene expression that does not modify the chromosomal DNA, and the result is referred to as a "transient knockdown".
In a transient knockdown, the binding of this oligonucleotide to the active gene or its transcripts causes decreased expression through a variety of processes. Binding can occur either through the blocking of transcription (in the case of gene-binding), the degradation of the mRNA transcript (e.g. by small interfering RNA (siRNA)) or RNase-H dependent antisense, or through the blocking of either mRNA translation, pre-mRNA splicing sites, or nuclease cleavage sites used for maturation of other functional RNAs, including miRNA (e.g. by morpholino oligos or other RNase-H independent antisense).
The most direct use of transient knockdowns is for learning about a gene that has been sequenced, but has an unknown or incompletely known function. This experimental approach is known as reverse genetics. Researchers draw inferences from how the knockdown differs from individuals in which the gene of interest is operational. Transient knockdowns are often used in developmental biology because oligos can be injected into single-celled zygotes and will be present in the daughter cells of the injected cell through embryonic development. The term gene knockdown first appeared in the literature in 1994
RNA interference (RNAi) is a means of silencing genes by way of mRNA degradation. Gene knockdown by this method is achieved by introducing small double-stranded interfering RNAs (siRNA) into the cytoplasm. Small interfering RNAs can originate from inside the cell or can be exogenously introduced into the cell. Once introduced into the cell, exogenous siRNAs are processed by the RNA-induced silencing complex (RISC). The siRNA is complementary to the target mRNA to be silenced, and the RISC uses the siRNA as a template for locating the target mRNA. After the RISC localizes to the target mRNA, the RNA is cleaved by a ribonuclease.
RNAi is widely used as a laboratory technique for genetic functional analysis. RNAi in organisms such as C. elegans and Drosophila melanogaster provides a quick and inexpensive means of investigating gene function. In C. elegans research, the availability of tools such as the Ahringer RNAi Library give laboratories a way of testing many genes in a variety of experimental backgrounds. Insights gained from experimental RNAi use may be useful in identifying potential therapeutic targets, drug development, or other applications. RNA interference is a very useful research tool, allowing investigators to carry out large genetic screens in an effort to identify targets for further research related to a particular pathway, drug, or phenotype.
This section may stray from the topic of the article. (April 2020)
A different means of silencing exogenous DNA that has been discovered in prokaryotes is a mechanism involving loci called 'Clustered Regularly Interspaced Short Palindromic Repeats', or CRISPRs. CRISPR-associated (cas) genes encode cellular machinery that cuts exogenous DNA into small fragments and inserts them into a CRISPR repeat locus. When this CRISPR region of DNA is expressed by the cell, the small RNAs produced from the exogenous DNA inserts serve as a template sequence that other Cas proteins use to silence this same exogenous sequence. The transcripts of the short exogenous sequences are used as a guide to silence these foreign DNA when they are present in the cell. This serves as a kind of acquired immunity, and this process is like a prokaryotic RNA interference mechanism. The CRISPR repeats are conserved amongst many species and have been demonstrated to be usable in human cells, bacteria, C. elegans, zebrafish, and other organisms for effective genome manipulation. The use of CRISPRs as a versatile research tool can be illustrated by many studies making use of it to generate organisms with genome alterations.
Another technology made possible by prokaryotic genome manipulation is the use of transcription activator-like effector nucleases (TALENs) to target specific genes. TALENs are nucleases that have two important functional components: a DNA binding domain and a DNA cleaving domain. The DNA binding domain is a sequence-specific transcription activator-like effector sequence while the DNA cleaving domain originates from a bacterial endonuclease and is non-specific. TALENs can be designed to cleave a sequence specified by the sequence of the transcription activator-like effector portion of the construct. Once designed, a TALEN is introduced into a cell as a plasmid or mRNA. The TALEN is expressed, localizes to its target sequence, and cleaves a specific site. After cleavage of the target DNA sequence by the TALEN, the cell uses non-homologous end joining as a DNA repair mechanism to correct the cleavage. The cell's attempt at repairing the cleaved sequence can render the encoded protein non-functional, as this repair mechanism introduces insertion or deletion errors at the repaired site.
So far, knockdown organisms with permanent alterations in their DNA have been engineered chiefly for research purposes. Also known simply as knockdowns, these organisms are most commonly used for reverse genetics, especially in species such as mice or rats for which transient knockdown technologies cannot easily be applied.
There are several companies that offer commercial services related to gene knockdown treatments.
- Summerton JE (2007). "Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity". Current Topics in Medicinal Chemistry. 7 (7): 651–60. doi:10.2174/156802607780487740. PMID 17430206. S2CID 12241724.
- Summerton J (December 1999). "Morpholino antisense oligomers: the case for an RNase H-independent structural type". Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1489 (1): 141–58. doi:10.1016/S0167-4781(99)00150-5. PMID 10807004.
- Nasevicius A, Ekker SC (October 2000). "Effective targeted gene 'knockdown' in zebrafish". Nature Genetics. 26 (2): 216–20. doi:10.1038/79951. PMID 11017081. S2CID 21451111.
- Wahlestedt, Claes (February 1994). "Antisense oligonucleotide strategies in neuropharmacology". Trends Pharmacol Sci. 15 (2): 42–6. doi:10.1016/0165-6147(94)90107-4. PMID 8165722.
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (February 1998). "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans". Nature. 391 (6669): 806–11. doi:10.1038/35888. PMID 9486653. S2CID 4355692.
- Pratt AJ, MacRae IJ (July 2009). "The RNA-induced silencing complex: a versatile gene-silencing machine". The Journal of Biological Chemistry. 284 (27): 17897–901. doi:10.1074/jbc.R900012200. PMC 2709356. PMID 19342379.
- Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, Ahringer J (November 2000). "Functional genomic analysis of C. elegans chromosome I by systematic RNA interference". Nature. 408 (6810): 325–30. doi:10.1038/35042517. PMID 11099033. S2CID 4373444.
- Aagaard L, Rossi JJ (March 2007). "RNAi therapeutics: principles, prospects and challenges". Advanced Drug Delivery Reviews. 59 (2–3): 75–86. doi:10.1016/j.addr.2007.03.005. PMC 1978219. PMID 17449137.
- Kamath RS, Ahringer J (August 2003). "Genome-wide RNAi screening in Caenorhabditis elegans". Methods. 30 (4): 313–21. doi:10.1016/S1046-2023(03)00050-1. PMID 12828945.
- Ghadakzadeh S, Mekhail M, Aoude A, Hamdy R, Tabrizian M (March 2016). "Small Players Ruling the Hard Game: siRNA in Bone Regeneration". Journal of Bone and Mineral Research. 31 (3): 475–87. doi:10.1002/jbmr.2816. PMID 26890411.
- Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS (July 2013). "CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes". Cell. 154 (2): 442–51. doi:10.1016/j.cell.2013.06.044. PMC 3770145. PMID 23849981.
- Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM (November 2013). "Orthogonal Cas9 proteins for RNA-guided gene regulation and editing" (PDF). Nature Methods. 10 (11): 1116–21. doi:10.1038/nmeth.2681. PMC 3844869. PMID 24076762.
- Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA (March 2013). "RNA-guided editing of bacterial genomes using CRISPR-Cas systems". Nature Biotechnology. 31 (3): 233–9. doi:10.1038/nbt.2508. PMC 3748948. PMID 23360965.
- Chen C, Fenk LA, de Bono M (November 2013). "Efficient genome editing in Caenorhabditis elegans by CRISPR-targeted homologous recombination". Nucleic Acids Research. 41 (20): e193. doi:10.1093/nar/gkt805. PMC 3814388. PMID 24013562.
- Hisano Y, Ota S, Kawahara A (January 2014). "Genome editing using artificial site-specific nucleases in zebrafish". Development, Growth & Differentiation. 56 (1): 26–33. doi:10.1111/dgd.12094. PMID 24117409.
- Gennequin B, Otte DM, Zimmer A (November 2013). "CRISPR/Cas-induced double-strand breaks boost the frequency of gene replacements for humanizing the mouse Cnr2 gene". Biochemical and Biophysical Research Communications. 441 (4): 815–9. doi:10.1016/j.bbrc.2013.10.138. PMID 24211574.
- Sun N, Zhao H (July 2013). "Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing". Biotechnology and Bioengineering. 110 (7): 1811–21. doi:10.1002/bit.24890. PMID 23508559. S2CID 6214542.
- "Adenoviral Gene Knockdown Cells". Sirion Biotech. Archived from the original on 9 July 2013. Retrieved 17 April 2013.